Add to ORKGPurpose. To evaluate the efficacy and toxicity of the sequential administration of paclitaxel (Taxol®; Bristol-Myers Squibb; Princeton, NJ), carboplatin (Paraplatin®; Bristol-Myers Squibb), and oral etoposide (VePesid®; Bristol-Myers Squibb) followed by gemcitabine (Gemzar®; Eli Lilly; Indianapolis, IN) and irinotecan (Campostar®; Pfizer Pharmaceuticals; New York, NY) in the first-line treatment of patients with carcinoma of unknown primary site. Patients and Methods. One hundred thirty-two patients were treated with sequential combination chemotherapy for a maximum of six cycles. All patients had relatively poor prognostic features. Fifty-nine patients had well-dif-ferentiated adenocarcinoma, 73 patients had poorly differ
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated w...
PURPOSE: To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide ...
PURPOSE: To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide ...
located on the World Wide Web at: The online version of this article, along with updated information...
Objective: We evaluated the efficacy and toxicity of combined paclitaxel and cisplatin chemo-therapy...
BACKGROUND. The purposes of this study were to evaluate efficacy and toxicity of the combination of...
BACKGROUND: : To date, the standard treatment for patients who have carcinoma of unknown primary ...
BACKGROUND: : To date, the standard treatment for patients who have carcinoma of unknown primary ...
About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its...
Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard first-line ...
<div><p>Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard fir...
The taxanes are the most active new agents for squamous-cell carcinoma of the head and neck (SCCHN) ...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated w...
PURPOSE: To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide ...
PURPOSE: To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide ...
located on the World Wide Web at: The online version of this article, along with updated information...
Objective: We evaluated the efficacy and toxicity of combined paclitaxel and cisplatin chemo-therapy...
BACKGROUND. The purposes of this study were to evaluate efficacy and toxicity of the combination of...
BACKGROUND: : To date, the standard treatment for patients who have carcinoma of unknown primary ...
BACKGROUND: : To date, the standard treatment for patients who have carcinoma of unknown primary ...
About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its...
Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard first-line ...
<div><p>Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard fir...
The taxanes are the most active new agents for squamous-cell carcinoma of the head and neck (SCCHN) ...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Improving survival in non-small cell lung cancer (NSCLC) will require new strategies or new drugs. S...
Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated w...